Cargando…
GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)
OBJECTIVE: To determine the efficacy and safety of intermittent docetaxel chemotherapy guided by circulating methylated glutathione S-transferase Pi-1 (mGSTP1) in men with metastatic castration-resistant prostate cancer (CRPC). PATIENTS AND METHODS: GUIDE (NCT04918810) is a randomised, two-arm, non-...
Autores principales: | Conduit, Ciara, Mak, Blossom, Qu, Wenjia, Lulio, Juliana Di, Burder, Ronan, Bressel, Matthias, Cusick, Thomas, Dhillon, Haryana M., Lourenço, Richard De Abreu, Underhill, Craig, Torres, Javier, Crumbaker, Megan, Honeyball, Florian, Linton, Anthony, Allen, Ray, Davis, Ian D., Clark, Susan J., Horvath, Lisa G., Mahon, Kate L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019311/ https://www.ncbi.nlm.nih.gov/pubmed/35465297 http://dx.doi.org/10.1177/17588359221092486 |
Ejemplares similares
-
Corrigendum to “GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)”
Publicado: (2022) -
Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011) -
Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
por: Petrioli, R, et al.
Publicado: (2011) -
Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015) -
Clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer
por: Lin, Guo-Wen, et al.
Publicado: (2019)